Today: 14 May 2026
Browse Category

Earnings Reports 24 February 2026 - 25 February 2026

Dow Jones today: DJIA rises 300 points with Nvidia earnings in the crosshairs

Dow Jones today: DJIA rises 300 points with Nvidia earnings in the crosshairs

The Dow rose 307.8 points to 49,482.3 in early afternoon trading Wednesday. Investors awaited Nvidia’s quarterly report, with options markets pricing a 5.6% post-earnings move, the smallest in three years. IBM climbed over 4%, while Axon Enterprise jumped on strong earnings. GoDaddy and Lowe’s fell after weak forecasts.
25 February 2026
···········
Wall Street climbs today as Nvidia earnings drive S&P 500, Nasdaq back to two-week highs

Wall Street climbs today as Nvidia earnings drive S&P 500, Nasdaq back to two-week highs

The S&P 500 and Nasdaq hit two-week highs Wednesday as tech shares rallied ahead of Nvidia’s earnings. Nvidia rose 2.2%, lifting chip stocks and sending the Philadelphia Semiconductor Index to a record. Axon Enterprise surged over 19% after strong results, while Lowe’s dropped 5% on a weak outlook. Tariff concerns and mixed forecasts kept trading uneven.
25 February 2026
····
Broadcom stock rises in early trade as Nvidia earnings loom and AVGO’s March 4 report nears

Broadcom stock rises in early trade as Nvidia earnings loom and AVGO’s March 4 report nears

Broadcom shares rose 2.3% to $332.83 in Wednesday morning trading, rebounding from a prior drop. The move tracked gains in tech stocks ahead of Nvidia’s earnings report later in the day. Broadcom is set to report quarterly results on March 4, with margins and VMware renewals in focus. Options trading showed heightened volatility, pointing to expectations of sharp moves around earnings.
25 February 2026
····
Fermi Inc (FRMI) stock price rises premarket as REIT tax risk and earnings date grab attention

Fermi Inc (FRMI) stock price rises premarket as REIT tax risk and earnings date grab attention

Fermi Inc shares rose 1.4% to $10.19 in premarket trading Wednesday after an 11.9% jump Tuesday. The company set March 30 for its fourth-quarter and full-year 2025 results call. Investors are watching a March 6 court deadline in a securities fraud class action and weighing risks to Fermi’s REIT tax status amid questions about its power sales.
25 February 2026
···
Ultra Clean (UCTT) stock pushes to $73 in premarket as earnings-fueled rally keeps running

Ultra Clean (UCTT) stock pushes to $73 in premarket as earnings-fueled rally keeps running

Ultra Clean Holdings shares rose about 1.5% premarket Wednesday to $73, after jumping 17% Tuesday on AI-driven wafer fab equipment optimism. Fourth-quarter revenue reached $506.6 million, with a GAAP net loss of $3.3 million and non-GAAP net income of $10 million. Needham raised its price target to $70. The company forecast first-quarter revenue of $505 million to $545 million.
25 February 2026
··
Archer Aviation stock climbs in premarket after patent suit vs Vertical, with earnings next week

Archer Aviation stock climbs in premarket after patent suit vs Vertical, with earnings next week

Archer Aviation shares rose 1.4% to $7.29 premarket Wednesday after disclosing a patent-infringement lawsuit against Vertical Aerospace in Texas federal court. Archer alleges Vertical’s “Valo” aircraft infringes patents tied to its “Midnight” model and seeks an injunction and damages. Vertical denies the claims. Traders are watching ahead of Archer’s March 2 earnings and cash guidance.
25 February 2026
···
Twilio stock steadies near $114 premarket as fresh 10-K shows profit swing, cash flow lift

Twilio stock steadies near $114 premarket as fresh 10-K shows profit swing, cash flow lift

Twilio reported 2025 net income of $33.8 million on $5.07 billion revenue in its annual 10-K, reversing a loss a year earlier. Shares hovered near $113.80 in premarket trading after closing Tuesday up 4.9%. The company listed 402,000 active customer accounts and $945.4 million in free cash flow. CFO Aidan Viggiano received 37,554 restricted stock units set to vest from March 2026.
25 February 2026
··
TransMedics (TMDX) stock jumps 7% premarket after earnings, 2026 revenue outlook

TransMedics (TMDX) stock jumps 7% premarket after earnings, 2026 revenue outlook

TransMedics Group shares jumped 7.3% premarket to $147.88 after posting Q4 revenue of $160.8 million, up 32%, and setting a 2026 revenue forecast of $727–$757 million. Net income for the quarter reached $105.4 million, boosted by an $83.8 million tax benefit. Adjusted earnings were 57 cents per share, topping analyst estimates. Gross margin slipped to 58% as clinical service and freight costs rose.
25 February 2026
··
Tempus AI (TEM) stock drops 4% in premarket as 2026 outlook lands after Q4 results

Tempus AI (TEM) stock drops 4% in premarket as 2026 outlook lands after Q4 results

Tempus AI shares fell 4.1% to $55.59 in premarket trading after the company set 2026 revenue guidance at $1.59 billion and projected adjusted EBITDA of $65 million. Fourth-quarter revenue jumped 83% to $367.2 million, with MRD test volume up 56% to about 4,700. The company still posted a net loss and relied on stock-based compensation. The stock closed Tuesday at $57.95.
25 February 2026
··
MercadoLibre stock set for a rough open after profit miss and margin squeeze hits MELI

MercadoLibre stock set for a rough open after profit miss and margin squeeze hits MELI

MercadoLibre shares dropped over 6% in after-hours trading Tuesday after missing quarterly profit estimates, with net income at $559 million versus the $587 million expected. Heavy spending on credit and logistics squeezed margins, despite a 45% revenue jump to $8.8 billion. The company’s credit portfolio surged nearly 90% to $12.5 billion. Investors are watching for management’s outlook on margin recovery.
25 February 2026
··
Stock market today: Dow futures steady as AI scare cools, Nvidia earnings and Trump tariffs loom

Stock market today: Dow futures steady as AI scare cools, Nvidia earnings and Trump tariffs loom

Japan’s Nikkei jumped 2.2% to 58,583.12 and the S&P 500 closed up 0.8% as Wall Street rebounded from a tech-led selloff. Anthropic launched 10 new AI plug-ins, boosting partner stocks such as Thomson Reuters and FactSet. AMD shares rose after a $60 billion AI chip deal with Meta. The U.S. began collecting a temporary 10% global import tariff, with a possible increase to 15% under consideration.
25 February 2026
··········
Coles share price slips as earnings loom and ACCC “Down Down” court fight hangs over stock

Coles share price slips as earnings loom and ACCC “Down Down” court fight hangs over stock

Coles Group shares fell 0.2% to A$21.82 on Wednesday as the ACCC pressed its case alleging Coles misled shoppers with some “Down Down” promotions. Justice Michael O’Bryan questioned the regulator’s framing; the trial resumes Thursday. Coles reports interim results Friday, with analysts expecting sales near A$23.77 billion and underlying NPAT of A$680–700 million.
25 February 2026
···
Broadcom stock dips after the bell as UBS flags VMware churn risk ahead of earnings

Broadcom stock dips after the bell as UBS flags VMware churn risk ahead of earnings

Broadcom shares fell 0.7% to $325.49 in after-hours trading Tuesday ahead of its March 4 earnings report. UBS reiterated a Buy rating and $475 target but flagged renewal risks in VMware contracts. Investors are focused on margins, AI-chip demand, and software growth tied to VMware. Broadcom also issued security patches for VMware Aria Operations this week.
24 February 2026
···
1 … 24 25 26 27 28 … 247

Stock Market Today

  • Nurix Therapeutics Stock: Is Its Premium 23.3x Price-to-Sales Multiple Justified?
    May 14, 2026, 9:02 AM EDT. Nurix Therapeutics (NRIX) shares rose 1.38% to $16.18 amid mixed recent performance, down 10% year to date but up nearly 69% over one year. The stock trades at a high price-to-sales (P/S) multiple of 23.3x, well above the US biotech average of 9.7x. This premium reflects strong analyst revenue growth forecasts of 42.2% annually, outpacing the broader market. However, Nurix remains loss-making with $295 million in ongoing losses and a $1.65 billion market cap, making it vulnerable to clinical setbacks. Investors should weigh the high growth potential against risks in this early-stage biotech before assuming the premium valuation is sustainable.

Latest articles

Apple Backs Google in EU AI Fight as iPhone Rules Loom

Apple Backs Google in EU AI Fight as iPhone Rules Loom

14 May 2026
Apple warned the European Commission that proposed EU rules forcing Google’s Android to open core features to rival AI assistants could endanger privacy, security, and device performance. The Commission’s feedback period closed Wednesday, with a final decision expected by July 27. Apple argued the measures could set a precedent for its own platforms. Google also opposes the plan, calling it an “unwarranted intervention.”
Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

14 May 2026
Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

14 May 2026
POET Technologies signed a supply and joint-development agreement with Lumilens, including a $50 million initial order for optical engines used in AI data-center networks. The companies said cumulative purchases could exceed $500 million over five years. POET shares rose 16% after the news. First engineering samples are expected in late 2026, with production targeted for 2027.
Go toTop